We are live on ! Find out more
TRIL

Trillium Therapeutics Inc.
TRIL

Delisted

TRIL was delisted on the 16th of November, 2021.

Back to rankings

19 hedge funds and large institutions have $2.1M invested in Trillium Therapeutics Inc. in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

0% more funds holding

Funds holding: 19 → 19 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

5% less capital invested

Capital invested by funds: $2.2M → $2.1M (-$102K)

Holders
19
Holders Change
–
Holders Change %
0%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$38.7K
2
Citadel Advisors
Citadel Advisors
Florida
+$11.8K
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$9.7K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$6.2K
5
VF
Virtu Financial
New York
+$5.22K

Top Sellers

Rank Fund Capital Flow
1
SB
Samsara BioCapital
California
-$24K
2
RIA
Realta Investment Advisors
Delaware
-$2.53K
3
Deutsche Bank
Deutsche Bank
Germany
-$2K
4
Two Sigma Investments
Two Sigma Investments
New York
-$777
5
Wells Fargo
Wells Fargo
California
-$507
Name Holding Trade Value Shares
Change 		Change in
Stake
MCMC
1
Matrix Capital Management Company
New Hampshire
$704K – – –
NMC
2
NEA Management Company
Maryland
$646K – – –
Morgan Stanley
3
Morgan Stanley
New York
$356K +$38.7K +114,400 +11%
BBA
4
Baker Bros. Advisors
New York
$155K – – –
TCM
5
Tekla Capital Management
Massachusetts
$137K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$31K – – –
VF
7
Virtu Financial
New York
$11K +$5.22K +15,443 +79%
Citadel Advisors
8
Citadel Advisors
Florida
$11K +$11.8K +34,899 New
UBS Group
9
UBS Group
Switzerland
$9K +$4.78K +14,143 +94%
Two Sigma Advisers
10
Two Sigma Advisers
New York
$9K +$9.7K +28,700 New
RIA
11
Realta Investment Advisors
Delaware
$7K -$2.53K -7,500 -22%
Two Sigma Investments
12
Two Sigma Investments
New York
$7K -$777 -2,300 -9%
BFM
13
Boothbay Fund Management
New York
$6K – – –
Bank of Montreal
14
Bank of Montreal
Ontario, Canada
$6K +$6.2K +18,333 New
Wells Fargo
15
Wells Fargo
California
$2K -$507 -1,500 -19%
LTFS
16
Ladenburg Thalmann Financial Services
Florida
$1K – – –
FDCDDQ
17
Federation des caisses Desjardins du Quebec
Quebec, Canada
$20 – – –
SB
18
Samsara BioCapital
California
– -$24K -71,619 Closed
Deutsche Bank
19
Deutsche Bank
Germany
– -$2K -8,500 Closed
Toronto Dominion Bank
20
Toronto Dominion Bank
Ontario, Canada
– +$186 +551 +383%
Royal Bank of Canada
21
Royal Bank of Canada
Ontario, Canada
– +$337 +997 +163%

TRIL Hedge Fund Activity: Q3 2019 in Review

19 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q3 2019, worth a combined $2.1M — down 4.6% from $2.2M a quarter earlier.

Fund positioning in TRIL was balanced in Q3 2019: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 3 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $38.7K. The largest seller was Samsara BioCapital, exiting entirely with an estimated $24K sold.

  • 19 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q3 2019, unchanged from Q2 2019.
  • Funds reported $2.1M of Trillium Therapeutics Inc. stock for Q3 2019, down 4.6% quarter-over-quarter.
  • 3 funds opened new Trillium Therapeutics Inc. positions in Q3 2019 and 3 closed out, a net change of 0 holders.
  • The largest Trillium Therapeutics Inc. buyer in Q3 2019 was Morgan Stanley, an estimated $38.7K added.
  • The largest Trillium Therapeutics Inc. seller in Q3 2019 was Samsara BioCapital, an estimated $24K sold.

Based on aggregated 13F filings for Q3 2019.